---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-006784"
form_type: "8-K"
ticker: "PRPH"
cik: "0000868278"
company_name: "ProPhase Labs, Inc."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:52:17.394826+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ProPhase Labs initiates sale process for BE-Smart esophageal cancer test; updates on COVID-19 receivable collections

## Summary
- Initiated potential sale or strategic partnership for BE-Smart, a CLIA/CAP-accredited LDT for esophageal cancer risk; outreach to >70 acquirers.
- Crown Medical Collections: >60% of aggregate claims are from commercial payors that partially reimbursed, implying higher recovery rates.
- Laboratory subsidiaries are in Chapter 11; legacy COVID-19 testing receivables being addressed via Crown Medical Collections initiative.

## SEC filing metadata
- accession: 0001493152-26-006784
- form_type: 8-K
- ticker: PRPH
- cik: 0000868278
- company_name: ProPhase Labs, Inc.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/868278/000149315226006784/0001493152-26-006784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/868278/000149315226006784/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-006784
- JSON: https://secwatch.observer/filing/0001493152-26-006784.json
- Plain text: https://secwatch.observer/filing/0001493152-26-006784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.